- Home
- ANAB vs OCS Comparison
ANAB vs OCS Comparison
Compare ANAB & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | OCS |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANAB | OCS |
|---|---|---|
| Price | $47.66 | $28.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $60.18 | $39.57 |
| AVG Volume (30 Days) | ★ 499.2K | 242.6K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $169,467,000.00 | $991,999.00 |
| Revenue This Year | $135.51 | $14.53 |
| Revenue Next Year | N/A | $691.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 196.42 | N/A |
| 52 Week Low | $12.21 | $14.00 |
| 52 Week High | $52.47 | $28.01 |
Technical Indicators
Market Signals| Indicator | ANAB | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 84.73 |
| Support Level | $46.06 | $26.13 |
| Resistance Level | $50.00 | $27.43 |
| Average True Range (ATR) | 3.02 | 1.38 |
| MACD | -0.05 | 0.43 |
| Stochastic Oscillator | 64.38 | 91.00 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.